Article Topic
Case overview, USA v John Thomas Howard, 2026 –
In October 2026, the U.S. Attorney’s Office in Western Virginia filed a criminal complaint against a CanaRx executive, charging him with illegally importing misbranded prescription drugs, conspiracy to commit fraud, and smuggling.
[...]PSM submits comment opposing HHS’s proposed peptide enforcement discretion policy
The policy would expose patients to unproven substances that FDA’s career staff recommended not be used in compounding because of safety and other concerns.
[...]She trusted her med spa with a “pharmacy grade” treatment. No one mentioned risks.
Paige Gordon asked her med spa about a peptide treatment. No one reviewed her health history or talked about potential risks. Months later, her cancer came back.
[...]Case overview: Eli Lilly and Co v InstantRx, et al (2026 — ) – ongoing
Eli Lilly filed a complaint against InstantRx and other defendants that allegedly distributed counterfeit and/or misbranded versions of Lilly-branded medicines through online pharmacy to pharmacy marketplaces.
[...]PSM files Citizen Petition with FDA to stop unsafe compounding of untested peptides
Partnership for Safe Medicines filed a citizen petition (CP) with the FDA asking them to refrain from taking action to allow for compounding of drug products using seven peptide bulk drug substances (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, and epitalon). Learn why here.
[...]Remembering Alex Boutin: the hidden risks of performance enhancing drugs
Alex took the advice of older gym veterans about how he could bulk up fast, setting off more than a decade of steroid and, eventually, unregulated peptide use.
[...]Judgment, USA v Brandon Piper
United States District Court Western District of Michigan Southern Division USA v Brandon Piper Judgment July 24, 2026 Read the document.
[...]Update on drug importation, October 2026
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
[...]Case overview, USA v LFA Machines, 2026 –
In September 2026, DEA arrested three LFA Machine employees for allegedly selling pill presses to customers who they knew or had reasonable cause to believe would use them to manufacture illicit controlled substances.
[...]Compounded GLP-1 crisis: what patients and policymakers need to know
Telehealth companies and mass compounders are selling knockoff GLP-1s to patients who believe they’re getting the real thing. They aren’t.
[...]